IVA

Inventiva S.A. [IVA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

IVA Stock Summary

Top 10 Correlated ETFs

IVA

Top 10 Correlated Stocks

IVA

In the News

IVA Financial details

Company Rating
-
Market Cap
185.92M
Income
-164.7M
Revenue
29.66M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
120
Optionable
No
Shortable
Yes
Earnings
25 Sep 2024
P/E
-3.19
Forward P/E
-
PEG
-0.17
P/S
17.23
P/B
3.81
P/C
-
P/FCF
-4.61
Quick Ratio
3.16
Current Ratio
3.47
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-3.74
EPS next Y
-
EPS next Q
-
EPS this Y
85.5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
13.68%
Revenue last 5Y
20.09%
Revenue Q/Q
719.36%
EPS Q/Q
-14.5%
-
-
-
-
SMA20
23.87%
SMA50
27%
SMA100
70.06%
Inst Own
-
Inst Trans
-
ROA
-47%
ROE
-81%
ROC
-0.67%
Gross Margin
100%
Oper. Margin
-469%
Profit Margin
-446%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.22-5.05
52W High
-37.8%
52W Low
+55.5%
RSI
63.33
Rel Volume
0.17
Avg Volume
40.6K
Volume
6.82K
Perf Week
-1.58%
Perf Month
23.41%
Perf Quarter
38.22%
Perf Half Y
41.36%
-
-
-
-
Beta
0.958
-
-
Volatility
0.19%, 0.29%
Prev Close
13.5%
Price
3.11
Change
14.76%

Something similar

Top by Market Cap
AMZ.DE
AMZN
AAPL
LLY.DE
BRK-A
Top Correlated ETFs
ZUT.TO
CEMB
LVHD
SRET
XDGH.TO
Top Correlated Stocks
EPRX.TO
CWEN
CWEN-A
OGS
FARM
Similar Market Cap
PVBC
ATOM
MEOA
1123.HK
SML.NZ

Company Profile

Healthcare Biotechnology
  • Volume Average 40.6K
  • Market Capitalization 185.92M
  • Employee 120
  • CEO Dr. Pierre Broqua Ph.D.
  • Headquarters Daix,FR
  • IPO Date 2020-07-10
  • Website https://www.inventivapharma.com

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.